Authors:
Monali Tayade, Shishanka Wangnoo
Download free PDF
Rabies Vaccine Market Size & Share 2026-2035
Report ID: GMI9865
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Rabies Vaccine Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Rabies Vaccine Market Size
The global rabies vaccine market was valued at USD 1.2 billion in 2025 and is projected to reach USD 1.9 billion by 2035, expanding at a 4.5% CAGR from 2026 to 2035.
Rabies Vaccine Market Key Takeaways
Market Leader: Sanofi led with over 15% market share in 2025.
Leading Players: Top 5 players in this market include Sanofi, Zoetis, Merck & Co., Bharat Biotech, Liaoning Cheng, which collectively held a market share of 48% in 2025.
Rabies demand is unusual among vaccine markets because exposure is often an acute clinical emergency rather than a discretionary preventive decision. Rabies remains almost invariably fatal after symptoms appear, while prompt post-exposure prophylaxis (PEP) is effective. The World Health Organization estimates that rabies causes about 59,000 deaths each year in more than 150 countries; dogs account for up to 99% of human transmission, and Africa and Asia account for approximately 95% of deaths [1]World Health Organization - Rabies Fact Sheet, 2024 - who.int. More than 29 million people receive PEP annually, creating a durable treatment base even where routine preventive vaccination remains limited.
The disease burden is concentrated where vaccine access is least reliable. Asia is estimated to account for 35,172 dog-mediated human rabies deaths annually, with India representing 59.9% of the regional total; Africa accounts for approximately 21,476 deaths [2]World Health Organization - Rabies Epidemiology and Burden - who.int. This mismatch between clinical need and recorded procurement defines the market's central commercial constraint. PEP spending in Asia alone can reach USD 1.5 billion annually, yet many exposed people still face travel costs, stockouts, incomplete regimens, or lack of rabies immunoglobulin.
Modern supply is centered on cell-culture technologies rather than historic nerve-tissue products. Baby hamster kidney (BHK), purified chick embryo cell (PCEC), and Vero cell vaccines support safer, scalable human vaccination programs. Intradermal administration is particularly consequential in high-burden settings because it can reduce vaccine volume requirements by 60%-80% compared with intramuscular delivery, allowing public programs to stretch constrained biologics budgets.
Human vaccines account for USD 839.4 million of 2025 market value and are forecast to reach USD 1,338.5 million by 2035. Veterinary vaccines account for USD 380.8 million in 2025 and are projected to reach USD 562.5 million by 2035. This division reflects the two linked interventions required for rabies control: treating exposed people and interrupting dog-mediated transmission through animal vaccination. The United Against Rabies collaboration's "Zero by 30" strategy seeks to end human deaths from dog-mediated rabies by 2030 through coordinated surveillance, PEP access, and mass dog vaccination.
Technology development is moving beyond established cell-culture platforms. AIM Vaccine has advanced a serum-free iterative purified Vero cell rabies vaccine toward marketing registration in China. Oxford University's ChAdOx2 RabG adenoviral-vector candidate, self-replicating RNA approaches, mRNA candidates, and recombinant nanoparticle products aim to reduce dose schedules or improve antigen design, although these platforms remain at different stages of validation and commercialization. Artificial intelligence is chiefly relevant upstream: immunoinformatics, epitope selection, and formulation modeling may shorten preclinical screening cycles, but in silico results should not be equated with clinical effectiveness.
GMI Analyst View
The market's 4.5% growth profile reflects a stable PEP demand floor rather than a uniformly expanding vaccination opportunity. In endemic settings, dog bites and weak animal-control systems keep PEP volumes high; in wealthier markets, wildlife exposure, occupational risk, and travel medicine sustain higher-value demand. The commercial consequence is a split market: suppliers serving public procurement must optimize supply reliability, dose efficiency, and eligibility for multilateral tenders, while suppliers in mature markets compete through product availability, regulatory maintenance, and access to travel-health and occupational-health channels.
"Zero by 30" changes the opportunity from isolated vaccine transactions to coordinated human-and-animal procurement. Its value is contingent on execution, however. Better case reporting can reveal unmet need and enlarge procurement plans, whereas underreporting suppresses the epidemiological evidence required to justify budgets. Companies with both human and veterinary capabilities, or with partnerships spanning these systems, are better positioned to benefit as countries convert elimination commitments into funded programs.
Key Drivers
Rabies Vaccine Market Driver Analysis
Increasing Incidence of Animal Bite Cases
Animal bites create immediate demand for clinical assessment and vaccine administration because rabies cannot be safely managed once symptoms emerge. WHO identifies dog bites as a major global health concern and reports that dogs account for 76%-94% of animal-bite injuries in low- and middle-income country datasets. In India, more than 3.7 million dog-bite cases were reported in 2024, alongside 54 reported human rabies deaths. Recorded mortality understates the underlying exposure burden, but bite presentations still generate recurrent PEP procurement needs.
The exposure pattern differs by market. In the U.S., domestically acquired human rabies is predominantly associated with bats, while raccoons, skunks, and foxes remain important wildlife reservoirs. These exposures support PEP and occupational PrEP despite the elimination of dog-mediated rabies transmission. In Asia and Africa, stray-dog populations and delayed access to care make dog-mediated exposure the larger driver. The result is a broad PEP base with different purchasing mechanics: insurance and provider networks in North America, versus public tenders and subsidized facilities in endemic countries.
Government-Led Rabies Elimination Programs
The Zero by 30 framework links public-health and veterinary action around a measurable goal: eliminating human deaths from dog-mediated rabies by 2030 [3]World Health Organization - Zero by 30: The Global Strategic Plan to End Human Deaths from Dog-Transmitted Rabies by 2030, 2018 - who.int. The United Against Rabies Forum coordinates governments, technical agencies, and partners across human health, animal health, and environmental systems. Its expansion has strengthened the case for integrated procurement, since canine campaigns lower exposure risk while PEP protects people already bitten.
India illustrates how policy can reshape demand visibility as well as vaccine volume. Its National Action Plan for Dog-Mediated Rabies Elimination works alongside the National Rabies Control Programme to improve PEP access, animal-bite reporting, and coordination toward the 2030 target [4]Press Information Bureau, Government of India - National Rabies Control Program and NAPRE-2030, 2024 - pib.gov.in. The national plan emphasizes availability of anti-rabies vaccine and serum throughout the health system and recognizes intradermal delivery as a cost-saving route. In the Americas, sustained PAHO-coordinated dog-vaccination and surveillance programs contributed to a reduction in human rabies cases from 300 in 1983 to five in 2024. These programs reduce disease but can temporarily increase formal vaccine demand as surveillance and referral systems improve.
Growing Awareness Regarding Preventive Vaccination
PrEP is smaller than PEP, at USD 267.0 million in 2025, but is expected to reach USD 460.9 million by 2035 at a 5.5% CAGR. The segment is driven by veterinarians, laboratory personnel, animal-control workers, wildlife professionals, and travelers whose risk persists before a known exposure. Updated recommendations and travel-health counseling can expand this group, particularly where access to dependable PEP is uncertain.
The commercial limitation is that PrEP does not eliminate the need for post-exposure medical assessment. That makes uptake sensitive to reimbursement, occupational policy, and perceived risk. In Europe, evidence cited in the supplied epidemiological package indicates that many eligible travelers remain unvaccinated, leaving a meaningful access and awareness gap. Manufacturers therefore need a different demand model for PrEP than for PEP: provider education, employer programs, and retail-vaccination access matter more than emergency-department inventory.
Expansion of Healthcare Access in Emerging Economies
Healthcare expansion changes the rabies market by bringing vaccines closer to the point of exposure. Rural facilities require reliable cold chains, trained staff, and predictable supply to initiate and complete multi-dose PEP. Intradermal regimens are strategically important because they allow countries to treat more people within a given vaccine budget. The gain is not simply lower unit use; it can improve continuity of treatment where procurement funds are fixed.
Channel development also supports this transition. Hospital pharmacies account for USD 770.7 million in 2025 because emergency assessment, wound care, vaccine administration, and potential immunoglobulin use are managed together. Yet retail pharmacies are forecast to grow at 5.6% CAGR, reaching USD 562.8 million by 2035, as PrEP and follow-up access move closer to communities. Online pharmacy revenue is projected to rise from USD 124.3 million to USD 205.0 million, although digital channels are more likely to facilitate information, scheduling, and prescription fulfillment than replace supervised injection.
Key Restraints
Rabies Vaccine Market Restraint Analysis
Limited Access in Low-Income Regions
The highest-burden communities often face the longest travel distances to facilities that hold vaccine and rabies immunoglobulin. WHO notes that PEP costs can average USD 108 when travel and lost income are considered, a prohibitive burden where daily incomes may be USD 1-2. Africa spends the least on PEP among high-burden regions while carrying a severe mortality burden, illustrating why market value is not a proxy for need.
Stockouts compound affordability barriers. A supply interruption after an exposure does more than defer one sale: it can disrupt a multi-dose course, reduce public trust in facilities, and undermine the case for timely care after later bites. Reporting on Indian shortages has highlighted the operational consequences of uneven supply and the importance of local manufacturing capacity and public procurement discipline. Manufacturers that can offer stable supply, suitable presentation formats, and predictable tender fulfillment have a material advantage in these settings.
High Cost of Post-Exposure Treatment
PEP is clinically more complex than a standard preventive vaccination visit. Wound management, multiple vaccine doses, and, for severe Category III exposures, rabies immunoglobulin or approved monoclonal antibody treatment can raise total treatment costs. The expense of immunoglobulin and its limited availability make the access problem more acute, especially in resource-constrained settings.
Intradermal administration and shorter validated schedules can reduce the burden of vaccine use and clinic visits, but they do not eliminate the need for trained assessment or severe-exposure biologics. Cost therefore shapes the market in two ways: it constrains patient completion in endemic areas and limits PrEP adoption among travelers or occupational groups without reimbursement. Products that reduce visit burden may create value only if health systems can incorporate them into protocols and procurement frameworks.
Underreporting of Rabies Cases
Underreporting distorts vaccine planning because fatal cases and bite exposures are frequently missed by surveillance systems. WHO identifies inadequate diagnostic capacity and weak surveillance as reasons why recorded rabies mortality is lower than the actual burden. When official data understate risk, countries may underbudget PEP, defer canine vaccination, and inadequately position stock at peripheral facilities.
The restraint also affects manufacturers' production decisions. Demand forecasts built on incomplete reporting can encourage conservative capacity allocation, even where actual exposure incidence is high. India's 2024 digital NRCP initiative is relevant because it seeks to improve real-time reporting of bites and suspected rabies cases, potentially improving both public-health response and demand visibility. Better reporting does not create disease, but it can convert hidden need into formal procurement.
Market Opportunity: Expansion of "Zero by 30" Global Initiative
The Zero by 30 initiative offers a route to narrow the gap between epidemiological burden and commercial access by aligning dog vaccination, surveillance, and human PEP systems. The opportunity is strongest for manufacturers able to meet public-sector requirements across human and veterinary programs. PAHO's progress in the Americas shows that sustained canine vaccination and coordinated public health action can sharply reduce human mortality, while the WHO neglected tropical disease roadmap frames rabies elimination as a broader health-system objective.
GMI Analyst View
Rabies vaccine demand is not constrained by a lack of clinical rationale; it is constrained by the ability to finance, identify, and reach exposed populations. This makes surveillance investment commercially consequential. As reporting systems improve, governments can quantify bite incidence, position inventory more accurately, and justify repeat procurement. Suppliers should therefore view digital reporting and public-health partnerships as demand-enablement infrastructure rather than activity outside the market.
The pre-2030 elimination window creates a timing asymmetry. Veterinary campaign capacity, tender eligibility, and local distribution relationships take years to establish, while national programs may accelerate spending as the target approaches. The near-term advantage belongs to companies that can support dependable public supply today, not merely companies with an emerging technical platform. Novel regimens can improve access, but their commercial impact depends on regulatory adoption, affordability, and incorporation into national protocols.
Rabies Vaccine Market Segment Analysis
Product Type
BHK vaccines lead the market with USD 492 million in 2025 and are projected to reach USD 717.5 million by 2035, at a 3.8% CAGR. Their established manufacturing base, particularly among Chinese suppliers, supports large-volume domestic procurement. Liaoning Cheng Da, Chengdu Institute of Biological Products, and AIM Vaccine are important participants in China's cell-culture vaccine ecosystem. BHK's scale advantage supports tender-driven volume, although its slower growth relative to Vero cell products suggests that platform mix will gradually change.
PCEC vaccines account for USD 281.3 million in 2025 and are forecast to reach USD 447.3 million by 2035, at a 4.7% CAGR. Bavarian Nordic's RabAvert/Rabipur franchise has an established position in high-income human-vaccine markets [8]Bavarian Nordic - Annual Report 2024, 2025 - bavarian-nordic.com. FDA records show continuing regulatory activity for RabAvert, supporting its lifecycle management in the U.S. PCEC's strategic value lies in its clinical familiarity and regulatory embeddedness rather than rapid volume expansion.
Vero cell vaccines generate USD 342.4 million in 2025 and are projected to expand to USD 576.5 million by 2035, at a 5.3% CAGR. Sanofi's Verorab is WHO-prequalified and used across numerous markets [5]World Health Organization - Global Market Study: Human Rabies Vaccines, Public Summary - who.int. Phase III evidence for lyophilized Vero cell products has supported both Zagreb and Essen schedules, reinforcing the platform's suitability for products designed around dose efficiency and storage practicality. Vero cell growth reflects both clinical familiarity and the prospect of differentiated formats for high-burden markets.
Other product types total USD 104.4 million in 2025 and are forecast to reach USD 159.8 million by 2035, at a 4.3% CAGR. This group includes human diploid-cell vaccines, recombinant products, and early-stage RNA technologies. Cadila Pharmaceuticals introduced ThRabis, a recombinant nanoparticle rabies vaccine using virus-like particle technology, in India in 2022 with a three-dose schedule on Days 0, 3, and 7. AIM Vaccine's serum-free candidate and self-replicating RNA programs indicate continuing platform diversification, but clinical development should be distinguished from approved commercial supply.
Type
Human vaccines account for USD 839.4 million in 2025 and are forecast to reach USD 1,338.5 million by 2035, at a 4.7% CAGR. PEP is the principal demand engine because it follows a recognized exposure and is usually procured through public-health or emergency-care pathways. WHO's market study identified 27 human rabies vaccines globally, but only four WHO-prequalified products during the study period, limiting the supplier pool eligible for some multilateral procurement channels.
Veterinary vaccines are valued at USD 380.8 million in 2025 and are projected to reach USD 562.5 million by 2035, at a 3.9% CAGR. Their economic role differs from human vaccines: they are a population-level prevention tool, especially in canine campaigns. Demand is supported by companion-animal vaccination requirements in mature markets and by government-led dog vaccination in endemic markets. The segment's growth rate is lower than that of human vaccines, but its relevance to Zero by 30 makes it strategically central.
Application
PEP represents USD 953.3 million in 2025 and is forecast to reach USD 1,440.1 million by 2035, at a 4.1% CAGR. Its 78.1% share reflects the clinical requirement to treat recognized exposures quickly. The PEP market is therefore operationally linked to emergency departments, public hospitals, assessment protocols, and access to immunoglobulin. Manufacturers must compete on supply assurance and regimen compatibility as much as on product differentiation.
PrEP is valued at USD 267.0 million in 2025 and is projected to reach USD 460.9 million by 2035, at a 5.5% CAGR. Growth is tied to occupational-risk protocols, travel medicine, and greater recognition that remote travelers may not have dependable PEP access. Its faster growth does not displace PEP; instead, it adds a more elective, channel-sensitive source of demand in North America, Europe, and affluent urban centers in Asia Pacific.
Distribution Channel
Hospital pharmacies lead the channel mix with USD 770.7 million in 2025 and are expected to reach USD 1,133.2 million by 2035, at a 3.9% CAGR. Their position reflects the clinical reality of PEP, where medical assessment, wound care, vaccine administration, and potential immunoglobulin use are managed together.
Retail pharmacies account for USD 325.2 million in 2025 and are forecast to rise to USD 562.8 million by 2035, at a 5.6% CAGR. The channel is most relevant to PrEP, travel medicine, and completion of prescribed courses where pharmacists are authorized to vaccinate or coordinate administration. Online pharmacies increase from USD 124.3 million in 2025 to USD 205.0 million by 2035, at a 5.1% CAGR. Their role is likely to remain complementary because rabies vaccines require regulated cold-chain handling and professional administration.
North America illustrates the segment interaction. BHK, PCEC, Vero cell, and other products are valued at USD 194.0 million, USD 111.2 million, USD 135.2 million, and USD 39.3 million, respectively, in 2025. Human vaccines account for USD 330.5 million and veterinary products USD 149.1 million. PEP represents USD 374.1 million compared with USD 105.5 million for PrEP, while hospital, retail, and online channels account for USD 303.5 million, USD 128.4 million, and USD 47.7 million, respectively. By 2035, the regional product segments are forecast to reach USD 263.7 million, USD 164.8 million, USD 212.2 million, and USD 56.1 million; human and veterinary segments USD 491.5 million and USD 205.4 million; PEP and PrEP USD 527.0 million and USD 169.9 million; and hospital, retail, and online channels USD 416.2 million, USD 207.3 million, and USD 73.4 million.
GMI Analyst View
The segment mix separates scale from growth. BHK products retain the largest revenue base because established manufacturing systems and domestic procurement networks favor dependable, high-volume supply. Vero cell vaccines grow faster because they combine cell-culture familiarity with potential formulation and logistics advantages. The commercial question is not whether one platform will abruptly displace another, but which suppliers can manage a gradual shift while retaining access to price-sensitive tenders.
PEP will remain the core volume market, but PrEP and retail access create a distinct higher-growth commercial lane. Suppliers focused on government programs need hospital and public-sector distribution strength; suppliers seeking PrEP growth need occupational-health, travel-clinic, and retail-pharmacy reach. Channel strategy therefore cannot be separated from product strategy, particularly as shorter schedules and new formulations move through clinical and regulatory pathways.
Rabies Vaccine Market Regional Analysis
North America
North America is valued at USD 479.7 million in 2025 and is projected to reach USD 696.9 million by 2035, at a 3.7% CAGR. The U.S. contributes USD 419.7 million, or 87.5% of regional revenue, and is forecast to reach USD 607.6 million by 2035. Canada contributes USD 59.9 million, or 12.5%, and is projected to reach USD 89.3 million.
The U.S. market is shaped by wildlife exposure rather than dog-mediated endemic transmission. CDC guidance identifies bats, raccoons, skunks, and foxes as key exposure considerations and supports use of Imovax and RabAvert for rabies prophylaxis [6]U.S. Centers for Disease Control and Prevention - Rabies Biologics - cdc.gov. Regulatory maintenance of RabAvert and Imovax sustains supply continuity in a market where PEP is clinically essential but incidence is relatively low. Canada follows a similar wildlife-risk profile, with companion-animal vaccination and public-health surveillance supporting veterinary and human vaccine demand.
Europe
Europe accounts for USD 223.2 million in 2025 and is forecast to reach USD 333.8 million by 2035, at a 4.0% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands are primarily characterized by traveler PrEP, occupational vaccination, imported exposure management, and selected wildlife risks rather than widespread dog-mediated transmission.
The UK gained an additional human-vaccine option when Sanofi launched Verorab in April 2024 following MHRA authorization in November 2023. Germany's large healthcare market and occupational-risk population support PrEP demand, while France, Spain, Italy, and the Netherlands rely on travel medicine and clinical readiness for imported cases. Europe's principal opportunity is raising PrEP uptake among eligible travelers and workers, not responding to the endemic dog-bite burden that defines Asian and African markets.
Asia Pacific
Asia Pacific is valued at USD 384.3 million in 2025 and is forecast to reach USD 656.7 million by 2035, at a 5.4% CAGR. The region combines the highest disease burden with expanding access, domestic production, and elimination-program activity. This makes it the principal source of incremental market value despite lower average product pricing than North America.
India is a critical demand and manufacturing center. Its high animal-bite burden, NRCP reporting systems, and NAPRE framework support large public-sector PEP requirements. Bharat Biotech's ChiroRab and IndiRab portfolio, Indian Immunologicals' Abhayrab, Cadila Pharmaceuticals' ThRabis, and Zydus Lifesciences' Rabivax-S illustrate the depth of domestic competition. Bharat Biotech acquired Chiron Behring's rabies vaccine assets in 2019 and has cited annual capacity of approximately 27 million doses across its portfolio.
China is a major volume market supported by domestic BHK and Vero cell production. AIM Vaccine, Liaoning Cheng Da, and Chengdu Institute of Biological Products compete in this setting, where domestic approvals, tender access, and production scale are decisive. Japan, Australia, and South Korea have lower endemic demand and rely more on occupational PrEP, travel medicine, and wildlife-related risk management. Australia's use case also includes Australian bat lyssavirus, for which rabies vaccination is relevant to exposed high-risk groups.
Latin America
Latin America is valued at USD 74.5 million in 2025 and is projected to reach USD 122.6 million by 2035, at a 5.0% CAGR. Brazil, Mexico, and Argentina benefit from a regional history of coordinated canine vaccination and human-rabies control. PAHO reports that the Americas reduced human rabies cases from 300 in 1983 to five in 2024, supported by extensive dog-vaccination campaigns.
Brazil remains the largest regional commercial market, supported by public procurement and ongoing exposure management. Mexico's progress against dog-mediated human rabies shifts demand toward surveillance, PEP availability, and wildlife-related risk. Argentina combines public-health demand with local veterinary biologics capability through BiogénesisBagó. The region demonstrates that disease-elimination progress can coexist with continued vaccine need: lower mortality may reduce emergency demand over time, but canine campaigns and surveillance maintain veterinary and public-sector purchasing.
Middle East & Africa
Middle East & Africa is valued at USD 58.6 million in 2025 and is forecast to reach USD 91.0 million by 2035, at a 4.4% CAGR. The region's low market value relative to its disease burden demonstrates the effect of affordability, access, and reporting constraints. Africa's estimated rabies mortality burden is substantial, but vaccine procurement remains constrained by facility reach and financing.
South Africa functions as a relatively developed reference market for surveillance and PEP availability in sub-Saharan Africa. Saudi Arabia and the UAE are more heavily influenced by traveler and expatriate PrEP demand, supported by stronger healthcare spending and private-sector access. Across the region, the most consequential variable is whether elimination financing can strengthen routine access to PEP and dog vaccination. PASERA and broader United Against Rabies partnerships provide a coordination framework, but implementation capacity remains uneven.
GMI Analyst View
Regional value and disease burden are inversely aligned in several parts of the market. North America generates the largest 2025 revenue because its reimbursement, provider networks, and product mix support higher value per treated exposure, even though its human mortality burden is comparatively low. Asia Pacific has the stronger growth outlook because high exposure volumes are increasingly meeting formal healthcare infrastructure and domestic manufacturing capability.
Middle East & Africa presents the largest gap between need and realized market value. This is not simply an underpenetrated private market; it is a financing and delivery problem that requires functional surveillance, public procurement, cold-chain availability, and proximity to care. Latin America offers a different lesson: integrated canine vaccination can sharply reduce mortality, but it does not eliminate demand for surveillance, veterinary supply, and PEP readiness. Regional strategy must therefore distinguish markets that need access expansion from markets where the priority is sustaining elimination gains.
Rabies Vaccine Market Share & Competitive Landscape
Competition is moderately concentrated, with Sanofi, Zoetis, Merck & Co., Bharat Biotech, and Liaoning Cheng Da collectively accounting for approximately 48% of global market value. Competitive advantage is determined by platform capability, regulatory approvals, WHO prequalification, manufacturing reliability, tender qualification, and reach across human or veterinary channels. The market does not operate as a single global product category: human PEP, travel PrEP, companion-animal vaccination, and canine elimination campaigns have different buyers and requirements.
Sanofi competes in human rabies vaccination through Imovax and Verorab. Its pipeline includes SP0087, a next-generation Vero cell candidate for which the company reported EMA review activity in 2025, with anticipated regulatory milestones in 2026 [7]Sanofi - 2025 Strong Sales and EPS Growth, January 29, 2026 - sanofi.com. Verorab's UK launch strengthened Sanofi's travel-health and clinical footprint. Bavarian Nordic's RabAvert remains an important PCEC product in the U.S. and other high-income markets; completion of its manufacturing transfer in 2024 reduced reliance on legacy external production arrangements.
Bharat Biotech combines ChiroRab and WHO-prequalified IndiRab, giving it relevance in Indian domestic demand and international procurement. Zydus Lifesciences also benefits from WHO prequalification for Rabivax-S, supporting access to multilateral procurement opportunities. Indian Immunologicals participates through Abhayrab, while Cadila Pharmaceuticals differentiates through the reduced-dose-schedule ThRabis product.
China's competitive structure is shaped by local manufacturing scale and product modernization. Liaoning Cheng Da's SPEEDA product uses a lyophilized Vero cell formulation and a Zagreb 2-1-1 regimen. AIM Vaccine is progressing serum-free and next-generation development programs, while Chengdu Institute of Biological Products remains a domestic supplier of cell-culture rabies vaccines. These companies compete in a market where local distribution and regulatory pathways are as important as platform technology.
Veterinary competition includes Zoetis, Merck & Co., Boehringer Ingelheim, Virbac, Elanco Animal Health, and BiogénesisBagó. Zoetis reported USD 9.3 billion in total 2024 revenue across its animal-health portfolio, supporting broad veterinary distribution capability. Merck & Co., through Merck Animal Health, participates in companion-animal and livestock biologics. Boehringer Ingelheim, Virbac, and Elanco Animal Health leverage established veterinary relationships across different geographic markets. BiogénesisBagó brings regional manufacturing and veterinary-procurement familiarity in Latin America. Their strategic importance increases where governments pair human PEP expansion with mass dog vaccination.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →